Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 10/25 04:24:17 pm
16780 ILa   +1.02%
10/20 TEVA PHARMACEUT : Announces FDA Acceptance of Resubmitted New Drug A..
10/19 REGENERON PHARM : and Teva Provide Update on Fasinumab Clinical Deve..
10/19 REGENERON PHARM : REGN), Teva Pharmaceutical Industries Ltd (NYSE:TE..
News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
07/01/2013 | 01:27pm CEST
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
10/20 TEVA PHARMACEUTICAL INDUSTRIES : Announces FDA Acceptance of Resubmitted New Dru..
10/19 REGENERON PHARMACEUTICALS : and Teva Provide Update on Fasinumab Clinical Develo..
10/19 REGENERON PHARMACEUTICALS INC (NASDA : REGN), Teva Pharmaceutical Industries Ltd..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Gets Trisenox Label Expansion
10/18 TEVA PHARMACEUTICAL INDUSTRIES : FDA suspends Teva, Regeneron back pain trial
10/18 TEVA PHARMACEUTICAL INDUSTRIES : to launch production of Copaxone in Russia
10/17 TEVA PHARMACEUTICAL INDUSTRIES : Regeneron and Teva Provide Update on Fasinumab ..
10/17 TEVA PHARMACEUTICAL INDUSTRIES : Regeneron and Teva Provide Update on Fasinumab ..
10/17 TEVA PHARMACEUTICAL INDUSTRIES : Receives Positive Opinion from European Medicin..
10/13 TEVA PHARMACEUTICAL INDUSTRIES : launches generic oral contraceptive
More news
Sector news : Pharmaceuticals - NEC
06:12p ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
01:59pDJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
01:53pDJMARKET SNAPSHOT : U.S. Stock Futures Point To Modest Gains, With Apple Set To Ta..
01:46pDJELI LILLY AND : Profit Dented by Higher Costs
11:41aDJGerman Companies Cling to Cash as Outlook Sours
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:37a What Is The Value Of Teva Without Copaxone Franchise?
08:13a My Dividend Growth Portfolio - Q3 2016 Summary
10/22 Generic drug makers scrambling to preserve marketing approvals of generic ver..
10/20 FDA accepts Teva's resubmitted application for deutetrabenazine; action date ..
10/18 In Less Than A Month, Regeneron's Luck Kicks In
Financials ($)
Sales 2016 22 447 M
EBIT 2016 7 361 M
Net income 2016 3 321 M
Debt 2016 25 826 M
Yield 2016 2,70%
P/E ratio 2016 9,87
P/E ratio 2017 8,15
EV / Sales 2016 3,11x
EV / Sales 2017 2,48x
Capitalization 43 961 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 68,2 $
Spread / Average Target 58%
Consensus details
EPS Revisions
More Estimates Revisions
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.60%310 823
ROCHE HOLDING LTD.-15.88%200 485
NOVARTIS AG-13.71%197 285
PFIZER INC.-0.46%194 889
MERCK & CO., INC.15.01%167 986
More Results